Related Experiment Video
Updated: May 16, 2026
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Dendritic cell-based vaccination for renal cell carcinoma: challenges in clinical trials
Jin Wang1, Lianming Liao, Jianming Tan
1Organ Transplant Institute, Fuzhou General Hospital, Xiamen University, Fuzhou, China.
Abstract:
After decades of research, dendritic cell (DC)-based vaccines for renal cell carcinoma have progressed from preclinical rodent models and safety assessments to Phase I/II clinical trials. DC vaccines represent a promising therapy that has produced measurable immunological responses and prolonged survival rates. However, there is still much room to improve in terms of therapeutic efficacy. The key issues that affect the efficiency and reliability of DC therapy include the selection of patients who will respond best to treatment, the proper preparation and administration of DC vaccines, and a combination of DC vaccination with other immune-enhancing therapies (e.g., removal of Tregs, CTLA-4 blockade and lymphodepletion). Additional antiangiogenic agents will hopefully lead to greater survival benefits for patients in early disease stages. This review focuses on the different approaches of DC-based vaccination against renal cell carcinoma and potential strategies to enhance the efficacy of DC vaccination.
Insights
Dendritic cell (DC) vaccines show promise for renal cell carcinoma, improving survival rates. Enhancing DC therapy efficacy requires better patient selection and combination with other immune-boosting treatments.
Area of Science:
- Immunology
- Oncology
- Vaccine Development
Background:
- Dendritic cell (DC)-based vaccines for renal cell carcinoma (RCC) have advanced to clinical trials.
- DC vaccines have demonstrated immunological responses and improved survival in RCC patients.
- Current therapeutic efficacy of DC vaccines for RCC requires improvement.
Purpose of the Study:
- To review current DC-based vaccination approaches for renal cell carcinoma.
- To explore strategies for enhancing the therapeutic efficacy of DC vaccination in RCC.
- To identify key factors influencing DC therapy success in RCC.
Main Methods:
- Review of preclinical and clinical trial data on DC vaccines for RCC.
- Analysis of factors affecting DC vaccine preparation, administration, and patient selection.
- Evaluation of combination therapies with DC vaccination for enhanced immune response.
Main Results:
- DC vaccines have shown measurable immunological responses and prolonged survival in RCC.
- Patient selection, vaccine preparation, and administration are critical for DC therapy efficacy.
- Combination strategies, including Treg removal and CTLA-4 blockade, show potential.
Conclusions:
- DC-based vaccines are a promising avenue for renal cell carcinoma treatment.
- Optimizing DC vaccine strategies through patient selection and combination therapies is crucial for improved efficacy.
- Further research into enhancing DC vaccination is essential for better patient outcomes in RCC.
